Rubén Tommasi

Io Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

27h-index3.4kcitations60works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotic Resistance in Bacteria(21), Antibiotics Pharmacokinetics and Efficacy(8), Chemical Synthesis and Analysis(7), Bacterial Genetics and Biotechnology(6), HIV/AIDS drug development and treatment(6)

Publications60 total

Chemoproteomics discovery of a CNS-penetrant covalent inhibitor of PIKfyve
2026Open Access
SALENT–IMA PREVENZIONE: ORGANIZATIONAL MODEL OF CONTINUITY CARE BETWEEN HOSPITAL AND TERRITORY
European Heart Journal Supplements·2025
<i>In vivo</i> dose response and efficacy of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against the <i>Acinetobacter baumannii-calcoaceticus</i> complex
Antimicrobial Agents and Chemotherapy·2023· 9 citedOpen Access
<b> <i>I</i> </b> <i>n vitro</i> pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against <i>Acinetobacter baumannii-calcoaceticus</i> complex
Antimicrobial Agents and Chemotherapy·2023· 25 citedOpen Access
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of <i>Acinetobacter baumannii-calcoaceticus</i> Complex (ABC) Infections
Open Forum Infectious Diseases·2022· 3 citedOpen Access
Rational design of a new antibiotic class for drug-resistant infections
Nature·2021· 135 cited
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics
Drug Discovery Today·2021· 29 citedOpen Access
N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay
Bioorganic & Medicinal Chemistry·2020· 18 citedOpen Access
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases
Journal of Medicinal Chemistry·2020· 59 citedOpen Access
Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
ACS Infectious Diseases·2020· 18 citedOpen Access
<i>In Vitro</i> Characterization of ETX1317, a Broad-Spectrum β-Lactamase Inhibitor That Restores and Enhances β-Lactam Activity against Multi-Drug-Resistant <i>Enterobacteriales</i>, Including Carbapenem-Resistant Strains
ACS Infectious Diseases·2020· 31 citedOpen Access
Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity
ACS Medicinal Chemistry Letters·2019· 40 citedOpen Access
EPIDEMIOLOGY/PREVENTION 2
European Heart Journal Supplements·2019Open Access
Titrating Levels of TolC in <i>E. coli</i>: A Sensitive Approach to Quantifying Efflux
ACS Infectious Diseases·2018· 2 cited
Role of the Klebsiella pneumoniae TolC porin in antibiotic efflux
Research in Microbiology·2018· 14 cited
Antibacterial Drug Discovery: Some Assembly Required
ACS Infectious Diseases·2018· 56 cited
<i>Acinetobacter baumannii</i> OmpA Is a Selective Antibiotic Permeant Porin
ACS Infectious Diseases·2017· 89 cited
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Nature Microbiology·2017· 262 cited
Design, Synthesis, and Properties of a Potent Inhibitor of<i>Pseudomonas aeruginosa</i>Deacetylase LpxC
Journal of Medicinal Chemistry·2017· 45 citedOpen Access
Whole-Cell-Based Assay To Evaluate Structure Permeation Relationships for Carbapenem Passage through the <i>Pseudomonas aeruginosa</i> Porin OprD
ACS Infectious Diseases·2017· 43 cited
page 1 of 3Next →

Frequent Co-authors

Alita A. Miller(18), John P. O’Donnell(9), John P. Mueller(9), Sarah M. McLeod(8), Samir H. Moussa(8), Thomas F. Durand-Réville(6), Adam B. Shapiro(6), Nicole Carter(6), Ramkumar Iyer(6), April Chen(6), Steve R. Turner(4), Joseph W. Strohbach(4), Paul K. Tomich(4), Kong-Teck Chong(4), Keith David Watenpaugh(4), Musiri N. Janakiraman(4), Suvit Thaisrivongs(4), Janelle Comita-Prevoir(4), Kirk Clark(4), Leslie W. McQuire(4)